1. Effectiveness and safety of an extended‐release tablet of sodium valproate for the prophylactic treatment of migraine: Postmarketing surveillance in Japan. Issue 4 (26th April 2016) Authors: Takeshima, Takao; Suzuki, Norihiro; Matsumori, Yasuhiko; Shimmoto, Naoki; Kurihara, Yuji; Gunji, Ryoji; Sakai, Fumihiko Journal: Neurology and clinical neuroscience Issue: Volume 4:Issue 4(2016:Jul.) Page Start: 134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial. Issue 10 (13th July 2017) Authors: Terauchi, Yasuo; Tamura, Masahiro; Senda, Masayuki; Gunji, Ryoji; Kaku, Kohei Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 10(2017) Page Start: 1397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J‐STEP/EL): A 12‐week interim analysis. Issue 5 (24th April 2016) Authors: Utsunomiya, Kazunori; Shimmoto, Naoki; Senda, Masayuki; Kurihara, Yuji; Gunji, Ryoji; Kameda, Hiroyuki; Tamura, Masahiro; Mihara, Hanako; Kaku, Kohei Journal: Journal of diabetes investigation Issue: Volume 7:Issue 5(2016:Oct.) Page Start: 755 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study. Issue 6 (28th May 2019) Authors: Terauchi, Yasuo; Fujiwara, Hisataka; Kurihara, Yuji; Suganami, Hideki; Tamura, Masahiro; Senda, Masayuki; Gunji, Ryoji; Kaku, Kohei Journal: Journal of diabetes investigation Issue: Volume 10:Issue 6(2019) Page Start: 1518 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS). Issue 5 (11th February 2018) Authors: Terauchi, Yasuo; Tamura, Masahiro; Senda, Masayuki; Gunji, Ryoji; Kaku, Kohei Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 5(2018) Page Start: 1176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study). Issue 6 (6th March 2017) Authors: Utsunomiya, Kazunori; Shimmoto, Naoki; Senda, Masayuki; Kurihara, Yuji; Gunji, Ryoji; Fujii, Shoko; Kakiuchi, Seigo; Fujiwara, Hisataka; Kameda, Hiroyuki; Tamura, Masahiro; Kaku, Kohei Journal: Journal of diabetes investigation Issue: Volume 8:Issue 6(2017) Page Start: 766 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study). Issue 2 (5th September 2019) Authors: Kaku, Kohei; Naito, Yusuke; Senda, Masayuki; Kurihara, Yuji; Gunji, Ryoji; Kakiuchi, Seigo; Utsunomiya, Kazunori Journal: Journal of diabetes investigation Issue: Volume 11:Issue 2(2020) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT). Issue 1 (8th July 2019) Authors: Utsunomiya, Kazunori; Senda, Masayuki; Kakiuchi, Seigo; Kameda, Hiroyuki; Tamura, Masahiro; Kurihara, Yuji; Gunji, Ryoji; Fujii, Shoko; Kaku, Kohei Journal: Journal of diabetes investigation Issue: Volume 11:Issue 1(2020) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT). Issue 2 (25th August 2020) Authors: Utsunomiya, Kazunori; Koshida, Ryusuke; Kakiuchi, Seigo; Senda, Masayuki; Fujii, Shoko; Kurihara, Yuji; Gunji, Ryoji; Kaku, Kohei Journal: Journal of diabetes investigation Issue: Volume 12:Issue 2(2021) Page Start: 184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT). Issue 4 (15th March 2020) Authors: Utsunomiya, Kazunori; Kakiuchi, Seigo; Senda, Masayuki; Fujii, Shoko; Kurihara, Yuji; Gunji, Ryoji; Koshida, Ryusuke; Kameda, Hiroyuki; Tamura, Masahiro; Kaku, Kohei Journal: Journal of diabetes investigation Issue: Volume 11:Issue 4(2020) Page Start: 906 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗